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Remnant-like lipoprotein particles (RLP)Since Zilversmit ﬁrst proposed postprandial lipemia as the most common risk of cardiovascular disease,
chylomicrons (CM) and CM remnants have been thought to be themajor lipoproteinswhich are increased in the
postprandial hyperlipidemia. However, it has been shownover the last twodecades that themajor increase in the
postprandial lipoproteins after food intakeoccurs in the very lowdensity lipoprotein (VLDL) remnants (apoB-100
particles), not CM or CM remnants (apoB-48 particles). This ﬁnding was obtained using the following three
analytical methods; isolation of remnant-like lipoprotein particles (RLP) with speciﬁc antibodies, separation and
detection of lipoprotein subclasses by gel permeation HPLC and determination of apoB-48 in fractionated
lipoproteins by a speciﬁc ELISA. The amount of the apoB-48 particles in the postprandial RLP is signiﬁcantly less
than theapoB-100particles, and theparticle sizes of apoB-48and apoB-100 inRLP are very similarwhenanalyzed
by HPLC. Moreover, CM or CM remnants having a large amount of TG were not found in the postprandial RLP.
Therefore, themajor portion of the TGwhich is increased in the postprandial state is composed of VLDL remnants,
which have been recognized as a signiﬁcant risk for cardiovascular disease.Faculty of Medicine, Gunma University, 3-39-22, Showa-m
a).
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Plasma triglycerides (TG) are known to be a surrogate for TG-rich
lipoproteins (TRL) and are present in chylomicrons (CM), very low
density lipoproteins (VLDL) and their remnants. TRL and their remnants
are signiﬁcantly increased in the postprandial plasma and are known to
predict the risk of coronary heart disease (CHD) [1,2], independent of
the total cholesterol, LDL or HDL cholesterol level. Recently, non-fasting
TG levels have come to be known as a signiﬁcant risk indicator for CHD
events [3–5]. Zilversmit [6] ﬁrst proposed that the postprandial CM is
the most common risk factor for atherogenesis in persons who do not
have familial hyperlipoproteinemia. The hypothesis of postprandial CM
and CM remnants came to be widely accepted as a major cause of
common atherogenesis, because it was well established that CM are
signiﬁcantly increased in the intestine after food intake and a large
amount of CM ﬂows into the blood stream through the thoracic duct.
Therefore, CM and CM remnants have been thought to be the major
lipoproteins in the postprandial hyperlipidemia until recently.
Furthermore, Type I and V chylomicronemia, which are associated
with severe lipemia, are often confused with common alimentary
lipemia. However, severe lipemia is most commonly associated with a
deﬁciency of lipoprotein lipase (LPL) or apoC II, and signiﬁcantly
elevated CM and CM remnants are detected in the fasting plasma of
these cases [7]. Type III hyperlipidemia is a kind of postprandial genetic
defectwhich results in signiﬁcantly elevated apoB48 inbeta-VLDL and is
associatedwith the low afﬁnity of apoE2/2 for the receptors which clear
remnant lipoproteins [8–11]. Alimentary lipemia is often reﬂected by
the increased turbidity of fat emulsions, not CM, in plasma in terms of
lipid concentrations. Therefore, the severity of lipemia in the postpran-
dial plasma often weakly correlates with the plasma triglyceride
concentration.
Nevertheless, many of the current textbooks on alimentary lipemia
or postprandial hyperlipidemia still indicate CM and/or CM remnants
as the major lipoproteins which are increased in plasma after food
intake. In addition, approximately 80% of the postprandial increase of
triglycerides has been considered to be accounted for by the apoB-48
containing lipoproteins until recently [12]. This is based on the fact
that the CM and/or CM remnants are the major triglyceride-carrier in
the postprandial state, with each particle carrying a very large number
of triglyceride molecules. Therefore, large quantities of triglycerides
are thought to be transported by a very small number of CM or CM
remnant particles. As the CM particle size has not been determined, it
has remained unclear whether the major TRL in the postprandial
plasma was CM-derived or not.
To investigate the characteristics of postprandial lipoproteins, we
developed a new immunoseparationmethodwhich enables the direct
isolation of remnant lipoproteins as remnant-like lipoprotein particles
(RLP) from the postprandial plasma and examination of the
concentration and particle size of CM and VLDL remnants [13,14].
This method has the capacity to isolate both CM and VLDL remnants
from the plasma simultaneously as RLP, which fulﬁll most of the
biochemical characteristics of CM and VLDL remnant lipoproteins.
In this manuscript, we have demonstrated that the major remnant
lipoproteins associated with postprandial hyperlipidemia are in fact
not CM remnants, but VLDL. To conﬁrm this ﬁnding, three new
analytical methods developed in Japan during the last two decades
were employed; the isolation of remnant-like lipoprotein particles
(RLP) using speciﬁc antibodies [13,14], separation and detection of
lipoprotein subclasses by a gel permeation high-performance liquid
chromatographic (HPLC) system [15] and determination of apoB48 in
fractionated lipoproteins by a highly speciﬁc ELISA [16].
2. Metabolism of CM, VLDL and their remnants in plasma
Fig. 1 shows the metabolic pathway of CM and VLDL. CM is secreted
by the intestine after fat consumption. CMparticles contain apoB-48 as astructural protein, which in humans is formed exclusively in the
intestine after tissue-speciﬁc editing of the apoB-100 mRNA [17,18]. It
appears that apoB-48 containing particles are continuously secreted
from the enterocyte, and at times of excessive triglyceride availability,
lipid droplets fuse with nascent lipoprotein particles, resulting in the
secretion of enormous chylomicrons [19,20]. Once the CM particle
reaches the plasma compartment, apoA-I dissociates very rapidly [21]
and acquires apoCs, in particular apoC-II, to enable efﬁcient unloading of
its massive triglyceride content after binding to the lipoprotein lipase
(LPL)which is bound to the endothelium [22]. High density lipoproteins
(HDL) are a major reservoir for the apoCs and apoE, but in conditions
with lowHDL concentrations (foundmost often inhypertriglyceridemic
subjects). CMmay receive apoCs and apoE from resident VLDL particles.
The half-life of CM triglycerides in healthy subjects is very short,
approximately 5 min [23]. The half-life of CM particles has been very
difﬁcult to estimate due to the difﬁculty of obtaining adequate labeling
of CM. The CM particle half-life is certainly longer than for CM
triglycerides and seems to be quite heterogeneous. Certain pools of
CMremnants have a very long residence time, at least as long as similar-
sized VLDL particles [24,25].
Furthermore, a major proportion of the CM remnants leave the
plasma compartment quite rapidly while still quite large, i.e., 75 nm in
diameter [24]. There is competition for lipolysis: CM and VLDL mix in
the blood and the two TRL species compete for the same lipolytic
pathway [25,26]. It has been shown that endogenous TRL accumulate
in human plasma after fat intake and the mechanism behind this
phenomenon is explained by the delayed lipolysis of the apoB-100
TRL particles due to competition with CM for the sites of LPL action
[26]. Similarly, endogenous TRL accumulate in rat plasma due to
competition with a CM-like triglyceride emulsion for the common
lipolytic pathway [27]. The increase in the number of TRL apoB-100
particles is actually far greater than that of the apoB-48 containing
lipoproteins in the postprandial state [28]. Of note, the accumulation
of large TRL apoB-100 particles seems to be a particular sign in
hypertriglyceridemic patients with CAD compared with healthy
hypertriglyceridemic subjects, suggesting a link between the accu-
mulation of large VLDL and the development of atherosclerosis [29].
VLDL particles are secreted continuously from the liver (Fig. 1). In
contrast to CM and their remnants, they are characterized by their
apoB-100 content. The secretion of VLDL is under complex regulation,
as the larger and more triglyceride-rich VLDL species are under strict
insulin control in a dual sense. First, a number of more or less insulin-
sensitive mechanisms regulate the availability of triglycerides for
VLDL production. The free fatty acids (FFA) which are generated by
lipolysis in adipose tissue through the action of hormone-sensitive
lipase provide a major source for hepatic VLDL secretion. Insulin
stimulates the endothelial expression of lipoprotein lipase (LPL), the
key enzyme in TRL metabolism, in a post-transcriptional manner
[30,31]. Hepatic uptake of poorly lipolyzed VLDL or CM remnant
particles may also contribute to the hepatocellular triglyceride
availability. Similarly, reduced uptake of FFA in adipose and muscle
tissues after LPL-mediated lipolysis of CM and VLDL shunts FFA to the
liver [32]. Finally, the liver has the capacity of de novo synthesis of
triglycerides and VLDL.
In contrast, the metabolic pathway of VLDL by hepatic triglyceride
lipase (HTGL) seems to be still controversial because of the difﬁculties
of measurements. HTGL has been reported to metabolize compara-
tively small remnant lipoproteins, although to a lesser extent than
LPL. However, our recent studies have shown no correlation between
HTGL activity and plasma TG, RLP-C, RLP-TG or the small dense LDL-C
concentration in humans [33], although we did ﬁnd a strong inverse
correlation between LPL activity and these parameters in both the
fasting and postprandial state (Table 1). Previous studies proposed
the concept of HTGL role to the remnant metabolism seemed to be
mainly based on the animal studies using anti-HTGL antibodies in
monkeys and rats and found the accumulation of remnant lipoproteins
Fig. 1. After fat intake, the intestine secretes chylomicrons (CM), the triglycerides of which are lipolyzed by lipoprotein lipase (LPL). The LPL reaction constitutes the initial process in
the formation of triglyceride-rich lipoprotein (TRL) remnants. The VLDL secretion process is partly regulated by the rate of FFA inﬂux to the liver. VLDL triglycerides are lipolyzed by
endothelial-bound lipoprotein lipase and VLDL remnant particles are formed. The ﬁnal TRL remnant composition is modulated by the cholesterol ester transfer protein (CETP)
reaction with HDL, hepatic lipase (HL), and the exchange of soluble apolipoproteins such as C-I, C-II, C-III and E. The great majority of the remnants are removed from plasma by
receptor-mediated processes and the principal receptors are the LDL receptor and the LDL-receptor-related protein (LRP). It is probable that the CM remnants use both of these
routes, whereas the VLDL remnants are more likely to use only the LDL receptor.
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well known that small dense LDL (sdLDL) is positively correlated
with TG and remnant lipoproteins in plasma, these data support the
concept that remnant lipoproteins are the precursor of sdLDL and are
metabolized in the same pathway by LPL [33]. From these data, HTGL
does not seem to play a signiﬁcant role in the metabolic pathway of
remnant lipoproteins, in contrast to previous reports [34–38], but
instead, plays a deﬁnitive role in HDL metabolism in humans.Table 1
Single linear regression analysis of plasma lipids, lipoproteins, lipases and ANGPTL3 in 20 v
TG RLP-C RLP-TG sdLDL
Fasting
TG –
RLP-C 0.72⁎⁎⁎ –
RLP-TG 0.88⁎⁎⁎ 0.91⁎⁎⁎ –
sdLDL-C 0.56⁎⁎⁎ 0.28 0.43⁎⁎ –
HDL-C −0.37⁎⁎ −0.19 −0.23 −0.36
LPL −0.43⁎⁎ −0.27⁎ −0.25 −0.22
HTGL −0.06 −0.01 0.02 −0.10
ANGPTL3 0.15 0.20 0.16 −0.12
Postprandial
TG –
RLP-C 0.86⁎⁎⁎ –
RLP-TG 0.95⁎⁎⁎ 0.86⁎⁎⁎ –
sdLDL-C 0.44⁎⁎ 0.36⁎⁎ 0.33⁎ –
HDL-C −0.42⁎⁎ −0.32⁎⁎ −0.42⁎⁎ −0.30
LPL −0.38⁎⁎ −0.40⁎⁎ −0.42⁎⁎ −0.21
HTGL 0.09 −0.05 0.24 −0.20
ANGPTL3 0.00 −0.22 −0.04 −0.12
⁎⁎⁎ pb0.001.
⁎⁎ pb0.01.
⁎ pb0.05.3. Biochemical characteristics of CM and VLDL remnants
TRL remnants are formed in the circulation when apoB-48 contain-
ingCMof intestinal origin or apoB-100 containingVLDLofhepatic origin
are converted by lipoprotein lipase (and to a lesser extent by hepatic
lipase according to the description commonly given in the literature)
into smaller and denser particles [36–38]. Comparedwith their nascent
precursors, TRL remnants are depleted of triglyceride, phospholipid,olunteers.
-C HDL-C LPL HTGL ANGPTL3
⁎⁎ –
0.33⁎ –
−0.49⁎⁎⁎ 0.08 –
0.36⁎⁎ −0.13 −0.50⁎⁎⁎ –
⁎ –
0.35⁎ –
−0.47⁎⁎⁎ −0.19 –
0.24 −0.27⁎ −0.25 –
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cholesteryl esters and apoE [39,40]. They can thus be identiﬁed,
separated, or quantiﬁed in plasma on the basis of their density, charge,
size, speciﬁc lipid components, apolipoprotein composition and
apolipoprotein immunospeciﬁcity [41]. Each of these approaches has
provided useful information about the structure and function of
remnant lipoproteins, and has helped to establish the role of TRL
remnants in thepathogenesis of atherosclerosis. Accuratemeasurement
and characterization of plasma remnant lipoproteins, however, have
proven to bedifﬁcult for the following reasons: [1] despite their reduced
size and triglyceride content, they are difﬁcult to differentiate from
their triglyceride-rich precursors; [2] due to their rapid plasma
catabolism, they exist in plasma at relatively low concentrations; and
[3] since remnants are at different stages of catabolism, they are
markedly heterogeneous in size and composition. TRL is known to
become progressively smaller, denser and less negatively charged as
they are converted into TRL remnants. They gradually lose triglycerides
and, in relative terms, become enriched with cholesteryl esters. They
also reduce their complement of C apolipoproteins (apoC-I, apoC-II, and
apoC-III), which are replaced by apoE. At any given time, there is a
continuous spectrum of different-sized remnants in the blood. Some of
these particles are of intestinal origin. They contain apoB-48 and are
present in greater concentrations after a fat-rich meal. The majority,
however in both the fed and fasted states, contains apoB-100 and is
derived fromthe liver. Dependingon theextent towhich theyhavebeen
lipolyzed, the different species of TRL contain different proportions of
triglyceride and cholesterol and may or may not contain apoCs or apoE.
Remnant lipoproteins are thus structurally and compositionally diverse,
which hasmade it necessary to develop a variety of speciﬁc biochemical
techniques for the detection, quantiﬁcation and characterization of
these lipoproteins. In the light of suchdifﬁculties,we endeavored toﬁnd
a new approach to isolate remnant lipoproteins — an approach which
could separate a variety of remnant lipoproteins from the normal
apoB100 (nascent VLDL and LDL) carrying lipoproteins. A speciﬁc anti-
apoB-100 antibody which does not recognize α-helix structure of
apoB-51 region was developed and used for the isolation of the apoE-
rich VLDL remnants (Fig. 2) [14].
4. Daily rhythm of plasma cholesterol, TG and remnant lipoproteins
and the changes in the lipoprotein levels after a fat load
The plasma triglyceride concentration ﬂuctuates throughout the
day in response to the ingestion of meals. Even if measured after a 10-
to 12-hour overnight fast (as is normal clinical practice), triglyceride
levels vary considerably more than LDL and HDL cholesterol levels.
As non-fasting TG levels are now known to be a signiﬁcant risk for
CHD events [3–5], the analysis of postprandial lipoproteins, rather
than the fasting state, has come to be recognized as more important.
We reported that non-fasting TG correlated more strongly with
remnant lipoproteins than fasting TG [42]. The correlations between
postprandial TG and remnant lipoprotein concentrations were
signiﬁcantly more robust when compared with fasting TG vs remnant
lipoprotein concentrations. In particular, the increase of postprandial
RLP-TG from fasting RLP-TG contributed to approximately 80% of the
increase of postprandial total TG from total fasting TG (Table 2). The
greater predictive value of non-fasting TG levels associated with
cardiovascular events is directly correlated with the increased levels
of remnant lipoproteins in the postprandial state.
As shown by Stanhope et al. [43] in Fig. 3 in their fructose treatment
study, plasma TG levels are signiﬁcantly increased during the day
associated with food intake. It was only in the early morning that TG
levels in all cases returned to the basal levels. When fructose was
administered, a signiﬁcant increase of TG after food intake compared
with the regular meal was observed. Plasma cholesterol levels did not
signiﬁcantly change during the day. Fig. 3 shows that blood samples
were collected every hour during the 24 h day. Between bloodsamplings, each subject consumed a standardized meal (9 am, 1 pm
and 6 pm) containing 55% of the energy as carbohydrate, 30% as fat and
15% as protein. The energy content of the meals was based on each
subject's energy requirementasdeterminedby theMifﬂin equation [44].
Fig. 3 shows that the TG levels in generally healthy volunteer plasma
were the highest at 2 AM in the very early morning, indicating that
postprandial conditions continue even past midnight during in the
course of a day, except in the earlymorning. Remnant lipoprotein levels
increased signiﬁcantly for most of the day except the early morning, a
similar proﬁle TG. These increasesmay depend on the kind of foods. The
typical carbohydrate rich Japanesemeal did not increase the levels of TG
and remnants during a given day comparedwith a fat-richmeal such as
in the typical Western diet [43,45], as shown by Ai et al. [46] and
Sekihara et al. [47].
Other postprandial studies have been conducted by oral fat load
test. One typical study performed in our laboratory was carried out in
6 male and 6 female (postmenopausal) Japanese volunteers aged 39–
60 (mean 52 years) who were generally healthy with no apparent
disease [48]. Among these 12 volunteers, there were three cases of
mild hyperlipidemia (Type IIb). All participants performed an oral fat
tolerance test (OFTT) as previously reported [49]. Brieﬂy, after a 12 h
fast, the subjects ingested 17 g fat/m2 body surface area (OFTT cream,
Jomo foods, Takasaki. Gunma). The test meal (OFTT cream) had a
water content of 56.9%, while lipids accounted for 32.9%, protein for
2.5%, carbohydrates for 7.4% and minerals for 0.3%. The fat was 64.3%
saturated, 29.3% monounsaturated and 3.5% polyunsaturated. Blood
samples were drawn before and 2, 4 and 6 h after an oral fat load.
Plasma apoB-48 signiﬁcantly increased and correlated with the TG
levels in postprandial plasma, however, apoB (more than 98% apoB-
100) did not (Fig. 4). These results suggest that CM or CM remnants
carrying a large amount of TG are the major component of the
increase in the postprandial remnant lipoproteins. However, the apoB
concentrationwas far greater than apoB-48 in the plasma, as shown in
Fig. 4. The apoB-100 in LDL decreased during a fat load, which resulted
in there being no change in apoB despite the increase of apoB100 in
the postprandial RLP.
The origin of the cholesterol increase in the postprandial TRL
remnants has been investigated by several researchers. Both a single
fatty meal and long-term diet have been reported to exhibit a
cholesterol accumulation in the TRL fraction less than expected, arguing
for a rather limited role of dietary cholesterol in determining the TRL
remnant cholesterol level [50,51]. In fact, the calculated proportion of
dietary cholesterol present in the CM fractionwas very low, i.e. only one
out of 99 cholesterol molecules originated directly from the meal [52].
Obviously, the dietary cholesterol is diluted by the cholesterol
undergoingenterohepatic recirculation, but thedelayed and incomplete
absorption of cholesterol (compared to triglycerides) also argues that
cholesterol and triglycerides are not incorporated at similar rates into
CMparticles. It is likely that themajority of the cholesterol is absorbed at
a later stage, further down in the gastrointestinal tract, where the
abundance of triglycerides is reduced. Therefore, in the postprandial
state the accumulation of cholesterol in CM remnant particles is limited
in comparison with the cholesterol-enrichment of VLDL remnants. The
major sourceof the cholesterol in theTRL remnants comes fromHDLasa
result of CETP activity, which will be described later in this manuscript.
5. Isolation of remnant-like lipoprotein particles (RLP) using speciﬁc
antibodies and the diagnostic characteristics of the RLP-cholesterol
(RLP-C) assay
An assay systembased on the recognition of TRL remnants according
to their apolipoprotein content and immune-speciﬁcity has been
developed that provides a quantitative and clinically applicable
approach to the measurement of plasma remnant lipoproteins [13,14].
This is theﬁrstmethod to separate remnant lipoproteins fromTRL using
speciﬁc antibodies so as to isolate the remnant fraction undermoderate
Fig. 2. The amino acid sequence of the epitope region of the anti-apoB-100 antibody (JI-H) is homologous to an amphipathic helical region of apoE, which suggests that apoE can
compete for binding of the antibody with the B-51 amphipathic helical epitope (2270–2321).
Ref. [14]: Nakajima et al. J Clin Ligand Assay 1996;19:177–83.
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fraction by immunoafﬁnity chromatography with a gel containing an
anti-apoA-I antibody and a speciﬁc anti-apoB-100 monoclonal
antibody (JI-H) (JIMRO II, Otsuka, Tokyo). The former antibody
recognizes all HDL and any newly synthesized CM containing apoA-I,
whereas the latter antibody recognizes all apoB-100 containing
lipoproteins, except for certain particles enriched in apoE. Anti-apoB-
100 antibody JI-H recognizes the B51 region of apoB100 and CM has no
epitope in this region. Therefore, CM lacking apoA-I, which is deﬁned as
the CM remnant [21], is not recognized by the gel and all of the apoB-48
particles in the plasma are isolated in the unbound RLP fraction. The
reason the anti-apoB-100 antibody does not recognize the apoE-Table 2
Lipids, lipoproteins, RLP-TG/RLP-C ratio and RLP-TG/total TG ratio after oral fat in 18 male
0 h 2 h
Median 75%tile Median
TC (mg/dL) 200 217 196
TG (mg/dL) 85 104 140⁎⁎
HDL-C (mg/dL) 62 74 62
RLP-C (mg/dL) 4.8 6.1 6.6⁎⁎
RLP-TG (mg/dL) 12 16 63⁎⁎
RLP-TG/RLP-C 2.5 2.7 8.7⁎⁎
RLP-TG/TG 0.13 0.15 0.45⁎⁎
ΔTG (mg/dL) – – 56
ΔRLP-TG (mg/dL) – – 51
ΔRLP-TG/ΔTG (ratio) – – 0.82
0 h vs 2 h, 4 h, and 6 h by U-test.
ΔTG; postprandial minus fasting (0 h) TG, ΔRLP-TG; postprandial minus fasting (0 h) RLP-T
⁎⁎ pb0.01.
⁎ pb0.05.enriched RLP is not entirely clear, although the amino acid sequence
of the epitope region of the apoB-100 antibody is homologous to an
amphipathic helical region of apoE, which suggests that apoE should be
able to compete for binding of the antibody to its epitope, located
between 2270 and 2320 amino acids fromN-terminal on apoB-100 [14]
(Fig. 2). The amphipathic helical peptide (2293–2301) of the chemically
synthesized antibody epitope reacted with the anti apoB-100 antibody
(JI-H) and exhibited potent reverse cholesterol transport activity as
apoA-I, apoE or HDL. Of further note, this peptide showed an inhibitory
effect on CETP activity as well (unpublished data).
HDL, LDL, large CM and the majority of VLDL are thus retained by
the gel. The unbound RLP are made up of remnant VLDL containingvolunteers.
4 h 6 h
75%tile Median 75%tile Median 75%tile
219 193 210 200 212
169 162⁎⁎ 206 125⁎ 139
73 60 71 61 75
7.7 7.1⁎⁎ 9.4 6.1⁎ 8
77 64⁎⁎ 101 39⁎⁎ 58
10.1 9.3⁎⁎ 13 5.8⁎⁎ 8.7
0.47 0.42⁎⁎ 0.56 0.34⁎⁎ 0.41
75 74 102 35 63
68 51 85 29 41
0.94 0.8 0.91 0.82 0.94
G.
Fig. 3. Twenty four-hour circulating plasma TG concentrations in subjects before and
after 2, 8 and 10 weeks of consuming fructose-sweetened beverages (n=17). The
plasma TG levels were found to be signiﬁcantly increased during the day associated
with food intake in a fructose treatment study. Only in the early morning did the TG
levels in all cases returned to the basal levels, and were highest in the middle of the
night. Blood samples were collected every hour for 24 h. Between blood samplings,
each subject consumed a standardized breakfast (9:00 h), lunch (13:00 h) and dinner
(18:00 h) containing 55% of the meal energy as carbohydrate, 30% fat and 15% protein.
Ref. [43]: Stanhope et al. J Clin Invest. 2009; 119:1322–34.
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in terms of cholesterol, although they can also be quantiﬁed in terms
of triglycerides or speciﬁc apolipoproteins (i.e., apoB, apoC-III, or
apoE) [53,54]. The plasma concentration of RLP-C has been shown to
be signiﬁcantly correlated with the plasma concentration of total TG,
VLDL-TG and VLDL-C. It has not been signiﬁcantly correlated with LDL
cholesterol or LDL apoB [55,56].
The physical and chemical properties of lipoproteins which are not
recognized by the apoB-100 monoclonal antibody JI-H, subsequentlyFig. 4. Postprandial changes in the plasma TG, apoB-48 and apoB concentrations before and
Ref. [48]: Nakano et al., Ann Clin Biochem. 2011; 48: 57–64.isolated by ultracentrifugation at a density 1.006 g/mL, have been
described [57]. These lipoproteins contained more molecules of apoE
and cholesteryl esters than those that were bound, consistent with
them being remnant-like lipoproteins. They had slow pre-b electro-
phoretic mobility compared with the bound VLDL fraction and ranged
in size from 25 to 80 nm. Other lipoproteins, however, may be present
when the JI-H monoclonal antibody (together with an anti-apoA-I
antibody) is used to isolate RLP by immunoafﬁnity chromatography
from total plasma in the absence of ultracentrifugation [13,14]. HPLC
analysis of RLP fractions isolated in this way from normolipidemic
and diabetic subjects [14], and fast protein liquid chromatographic
analysis of RLP from type III and type IV patients [54], have revealed
considerable size heterogeneity in RLP, with particles ranging in size
from VLDL to LDL. The relative amount of lipid and apolipoprotein
in RLP can also vary considerably from one individual to another.
Hypertriglyceridemic patients have more triglyceride and apoC-III,
and less apoE, relative to the apoB in RLP, than do normolipidemic
subjects [53,54]. Hypertriglyceridemic patients invariably have
elevated levels of RLP-C, and the clinical usefulness of this assay
depends on the studies which show that RLP-C concentration predicts
the presence of coronary or carotid atherosclerosis independently of
the plasma triglyceride level [58,59].
The median concentration of RLP-C is 5.9 mg/dL in 35- to 54-year-
oldAmericanmenand4.6 mg/dL in similarly-agedwomen [56]. RLP-C is
higher in older vs younger subjects,[13,55], men vs women [55,56],
postmenopausal vs premenopausal women [55], the fed vs the fasted
state [49,60], individuals with diabetes [61], patients with familial
dysbetalipoproteinemia,[13,54,62,63], hemodialysis patients [47,64]
and patients with coronary artery restenosis after angioplasty [65]. It
has been demonstrated that the RLP-C concentration is signiﬁcantly
higher in patients with CAD than in control subjects [13,55,56,66–68].
The potential atherogenicity of RLP-C is supported by the observation
that RLP can promote lipid accumulation in mouse peritoneal
macrophages [69], stimulate whole-blood platelet aggregation [70,71]
and impair endothelium-dependent vasorelaxation [72]. The physio-
logical and pathophysiological aspects of RLP have been investigatedafter an oral fat load. TG displayed a close correlation with apoB-48, but not with apoB.
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diseases [73], but relatively little is known about the biochemical
composition of RLP or the extent to which this composition varies from
one individual to another.
6. Fractionation and analysis of RLP with a gel permeation
HPLC system
Gel permeation HPLC is a method for quantifying lipoproteins by
particle size [15,74]. Online post column detection of lipid compo-
nents in lipoproteins particles after separation by size provides
quantitative lipoprotein size distribution fromwhole serum or the RLP
fraction. The following combined techniques were used: 1) TSKgel
LipopropakXL columnswhich can separate awide range of lipoprotein
particle sizes from CM to HDL [75], 2) an on-line enzymatic reaction
for TC and TG in the separated efﬂuents from the column [76] and 3)
20 component peak analysis using a Gaussian curve ﬁtting technique
[77]. These techniques can provide CM-cholesterol (CM-C), VLDL-
cholesterol (VLDL-C), LDL-C, HDL-C, and total cholesterol (TC) and
their triglycerides (CM-TG, VLDL-TG, LDL-TG, HDL-TG and total TG)
together with their VLDL, LDL and HDL subclasses. This HPLC method
has satisfactory performance on sensitivity, reproducibility and
accuracy compared to the reference methods [75]. The LipoSearch
HPLC analytical service for the TC and TG concentration in the major
subclasses of lipoproteins was conducted at Skylight Biotech, Inc
(Akita, Japan: http://www.skylight-biotech.com/eng/service.html).
This HPLC system is appropriate for the proﬁling of TG rich
lipoproteins and postprandial samples because of its capacity to
separate CM and VLDL. The high sensitivity of this method enables an
examination of the particle size distribution in the RLP fractions
separated by immunoseparation gels, which are very low in con-
centration compared with LDL and HDL in plasma. Moreover, the dual
detection system of TG and TC provides useful information for
determining the heterogeneity of the RLP particles separated by
immunoafﬁnity gels. Using 100 μL of supernatant in immnoafﬁnity gel
suspension solution after 2 h of incubation (5 μL serum or plasmawith
300 μL immunoafﬁnity gel solution), the RLP-C and RLP-TG proﬁles
can be directly observed with an on-line dual detection method using
gel permeation HPLC [76]. Fig. 5 shows a typical proﬁle of the
postprandial RLP monitored by TC and TG reagents in normolipidemic
and hyperlipidemic cases after a fat load [48]. The particle sizes are
shown in a range of VLDL to LDL before (0 h) and after (2, 4, 6 h) an
oral fat load. A small peak at the void retention time was detected at
2 h and 4 h, in each case as large TG-rich lipoproteins. The clearance of
the VLDL fraction was signiﬁcantly delayed in a hyperlipidemic
subject compared to a normolipidemic subject.
Another approach is to isolate a large amount of RLP from theplasma
for further HPLC fractionation. For example, 0.2 mL aliquots of plasma
were applied to columns containing 2 mL of immunoafﬁnity mixed gel.
The plasma sampleswere incubatedwith the immunoafﬁnitymixed gel
at room temperature for 30 min. Lipoproteins unbound from the gel
(containing primarily CM and VLDL remnants) were eluted with 3.5 mL
of 10 mMphosphate buffered saline (pH7.2). The unbound fractionwas
concentrated with an Amicon Ultra ﬁlter (Millipore, USA) for HPLC
fractionation and analysis. The concentrated RLP fraction was fraction-
ated by HPLC and 0.35 mL of aliquot in each tube was collected for the
determination of TC, TG, apoB-48 and apoB-100 [48].
7. Determination of serum apoB-48 with ELISA
The characteristics and development of the apoB-48 ELISA assay
using monoclonal antibodies have been reported by the two groups in
Japan [16,78,79]. The ELISA for apoB-48 for this studywas obtained from
Shibayagi (Shibukawa, Gunma) [16]. The assay uses a monoclonal
antibody raised against a C terminal decapeptide of the apoB-48 protein
and was calibrated using recombinant apoB-48 antigen [80]. Themonoclonal antibody has no cross-reactivity with apoB-100, as veriﬁed
byELISAandWesternblotting,withmore than90% recoveryof apoB-48,
and the assay has within- and between run coefﬁcients of variation of
4.8% and 5.4%, respectively . The assay was tested in healthy fasting
Japanese volunteers with mean reported values of 0.460±0.15 mg/dL
(range 0.27–0.81 mg/dL). In healthy volunteers tested at 0, 2, 4 and 6 h
after a 40 g fat load, serum apoB-48 and TG increased approximately
2-fold, with a similar peak time of 3 to 4 h [16,79]. The apoB48 ELISA
determined the apoB48protein in the large TG-rich lipoprotein particles
in severe lipemic plasma by pre-treatment with detergent (0.1% Triton
X-100). The assay had a sensitivity of 0.25 ng/mL; and a linear dynamic
rangeat2.5 to40 ng/mL. Interferencewith theassay valueswasnoted in
the hemoglobin values of at least 106 mg/dL and bilirubin values of at
least 10 mg/dL. To further validate this assay, whole plasma and the TRL
fraction (after subjecting plasma to ultracentrifugation at its own
density of 1.006 g/mL for 18 h) was studied [81]. TRL samples were
subjected to gel electrophoresis for the separation of apoB-100 and
apoB-48, followedbygel scanning, and showed that themeanTRL apoB-
48 value was 1.01 mg/dL (SD, 0.43 mg/dL) using ELISA and 0.50 mg/dL
(SD, 0.20 mg/dL) using gel scanning. The correlation coefﬁcient or r
value between the 2 methods was 0.82 [81], highly correlated. There-
fore, although the 2methods correlate well, and the gelmethod yielded
TRL apoB-48 concentrations that were approximately 50% lower than
the ELISA values, indicating that a correction factor of 2.02 would need
to be applied to prior kinetic studies [12] in which the TRL apoB-48
levels had been assessed by gel scanning. Furthermore, Nakano et al.
[82] determined the concentration of apoB-48 and apoB-100 carrying
lipoprotein particles extracted from human aortic atherosclerotic
plaques in sudden death cases. The plasma apo-B48 level was shown
to be signiﬁcantly elevated in type III cases, as previously reported
[54,79]. Therefore, this method was applicable to the determination of
the apoB48 concentration in the fractionated RLP using anHPLC system.
8. Postprandial remnant metabolism in CETP deﬁciency
Plasma cholesteryl ester transfer protein (CETP) mediates the CE/
TG exchange from HDL to TG-rich lipoproteins which forms remnant
lipoproteins (Fig. 1). Fielding et al. [83] reported that CETP activity
was signiﬁcantly increased in the postprandial state almost in parallel
with the increase of plasma TG. The RLP-C and RLP-TG levels were
increased along with elevated CETP activity in patients with nephrotic
range proteinuria [84]. Therefore, CETP activity and remnant
formation are evidently closely associated.
CETP deﬁciency results in a low LDL/high HDL phenotype
including apoE-rich large HDL. Large HDL may provide cholesteryl
ester and apoE to CM/VLDL during lipolysis in the postprandial state,
accelerating remnant lipoprotein formation and uptake in the liver. To
investigate the role of CETP in postprandial lipoprotein metabolism,
the lipid levels of plasma RLP were determined in one homozygous
and three heterozygous CETP deﬁciency cases and controls with an
apoE3/3 phenotype by Inazu et al. [85]. After oral fat-load, the area
under the curve (AUC) of the TG, RLP-TG and apoB48 levels was
remarkably decreased in heterozygous CETP deﬁciency as compared
to the controls (Fig. 6). Similarly, the homozygote had a signiﬁcantly
low AUC for the TG, RLP-TG and apoB-48 levels.
HPLC analysis in the homozygote showed that the increased RLP-C
was not due to the conventional VLDL size RLP, but to those of large
HDL size. In heterozygotes, a bimodal distribution of the RLP-C level
was found for the conventional VLDL and large HDL sizes. Subjects
with CETP deﬁciency appeared to have low levels of TG response and
diminished remnant lipoprotein formation after a fat-load.
Ai et al. [86] also found a unique proﬁle of serum postprandial
RLP-C and RLP-TG during a fat load in a male CETP deﬁciency patient,
aged 40, whose serum HDL-C, apo-AI and TG levels were abnormally
elevated. From the genetic analysis, this case was a compound het-
erozygote with a known mutation of Intron 14G(+1)NA and R268X.
Fig. 5. Typical proﬁles of RLP-TG and RLP-C in the postprandial plasma of a normolipidemic (TGb150 mg/dL) and a hyperlipidemic (TGN150 mg) subject after oral fat load. The RLP
fraction was monitored by TC and TG with an HPLC system. After 5 μL serum was incubated with 50 μL of immnoafﬁnity gel (300 μL of gel suspension solution) for 2 h as the RLP-C
assay, 100 μL of the supernatant of the unbound fractionwas applied to the HPLC system. RLPwas always detected with a large VLDL particle size (thin line; RLP-C, thick line; RLP-TG)
and a small peak in the void fraction composed of the CM size. The clearance of RLP-C and RLP-TGwas delayed in the hyperlipidemic case, while clearance in the normolipidemic case
returned to the basal level in 6 h.
Ref. [97]: Nakano et al., Clin Chim Acta 2011; 412: 71–78.
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previously in the Japanese population. This is the reason the CETP
level was less than the detectable limit. Because of this CETP
deﬁciency, HDL is unable to exchange its cholesteryl ester with the
TG of other lipoprotein particles, including RLP [85–87]. In this case, it
is not clear whether the CETP deﬁciency was the cause of the proﬁle of
the postprandial RLP-C and RLP-TG. A similar CETP deﬁcient case with
abnormally elevated TG was previously reported by Ritsch et al. [88]
and precise genetic analysis of CETP was performed to ﬁnd the cause
of the dissociation between the cholesteryl ester and TG transporta-
tion in plasma. However, they could not ﬁnd any speciﬁc cause in that
case, and she was completely CETP deﬁcient as well as being an apo-
E2 carrier. The serum levels of RLP-C and RLP-TG as well as total TG
usually increase and decrease in parallel after an oral fat load in
normal individuals. Also, both RLP-C and RLP-TG in CETP deﬁcient
cases are usually reduced, as reported by Inazu et al. [85]. However, in
this case subject, the serum RLP-C level was highly elevated in the
fasting state and did not increase after a fat load, but rather decreased,
while the RLP-TG and total TG levels signiﬁcantly increased after a fat
load, with a delayed peak time compared with normal control
subjects. This phenomenon indicated that CETP and HDL played an
important role in the formation of RLP-C (but not RLP-TG), as has been
reported for postprandial lipid metabolism in homo- and heterozy-
gous CETP deﬁciency cases [85] and the in vitro formation of RLP withCETP deﬁciency by Okamoto et al. [87]. However, interestingly, the
RLP-TG and total TG levels in this case subject increased signiﬁcantly
at 240 min after a fat load, like those in common hyperlipidemic
cases. The trend of the case subject was similar to that of individuals
treated with estrogen, whose serum RLP-C level is reduced, but RLP-
TG level increases, after the treatment [89,90]. This means that the
major metabolic pathways of RLP-C and RLP-TG in the postprandial
state are controlled independently, although the RLP particle itself
is of the same structure as other lipoproteins i.e. composed of TC,
TG, phospholipids and apolipoproteins, and isolated by the same
immunoseparation method. In the case subject, found an extremely
elevated plasma ANGPTL3 level, which was discovered as an
inhibitory modulator of LPL and HTGL in mice [91]. However, it was
recently reported that ANGPTL3 associates more strongly with EL or
HTGL, which controls HDL-Cmetabolism, but not with TG or remnants
in humans [33,92]. As the case subject Ai et al. reported [86] showed
nearly normal LPL and HTGL activity in post-heparin plasma,
ANGPTL3 was shown not to affect RLP-TG levels associated with LPL
and HTGL activities [33]. However, the lack of CETP together with
enhanced EL or HTGL inhibition by elevated ANGPTL3 may have
affected a signiﬁcantly increase of the HDL-C level, especially apo-E-
rich HDL in this case.
Another interesting dissociation between RLP-C and RLP-TG in the
postprandial plasma was observed in one of the heterozygous CETP-
Fig. 6. The plasma TG, RLP-C, RLP-TG and apoB-48 concentrations after a fat-load. The bars indicate the S.E.M. and each time point is shown for the homo-, heterozygotes and controls.
The open circles indicate controls; half-shaded circles indicate heterozygotes; closed circles indicate data from a CETP-deﬁcient homozygote as a reference. CETP deﬁciency results in
a signiﬁcantly reduced TRL remnant formation in the postprandial state.
Ref. [85]: Inazu et al. Atherosclersois 2008; 196: 953–57.
1314 K. Nakajima et al. / Clinica Chimica Acta 412 (2011) 1306–1318deﬁcient subjects (CC-2) after a fat load [86]. The serum RLP-C and
RLP-TG levels reportedly increase and decrease in parallel after an oral
fat load in most of the study cases [45,93,94]. However, one
heterozygous CETP-deﬁcient subject with increased RLP-C and RLP-
TG (VLDL size remnants) after a fat load exhibited RLP-TG which
started to separately decrease at 240 min and RLP-C in 360 min. This
dissociationmay be associatedwith themagnitude of CETP deﬁciency,
in which case CC-2 still enhances the formation of VLDL size RLP-C and
RLP-TG, but is apparently insufﬁcient to complete the normal
pathway between CETP and LPL [95]. These cases may be associated
with some genetic disorder of either CETP or its activity, resulting in
the dissociated clearance of RLP-C and RLP-TG.
As LPL metabolizes TRL and CETP enhances the formation of both
CM and VLDL remnants, the balance of LPL and CETP activity may
determine the major components of the postprandial remnant
lipoproteins. Further, CETP deﬁciency itself may not be atherogenic,
whereas together with elevated RLP it may be atherogenic and pose a
risk for CHD. These cases may help to clarify the controversy whether
CETP deﬁciency is atherogenic or not.
9. RLP-TG as a marker for the analysis of postprandial
remnant lipoproteins
RLP-C has been considered as a risk factor for cardiovascular disease
for the last two decades. Most of the studies in the literature have
reported the RLP-C concentration in the fasting state [73]. The lack of
sensitivity of the TGmeasurement in the RLP fraction made us delay an
intended investigation of RLP-TG. Recently, we have established a
satisfactory assay of RLP-TG which enabled us to determine the
concentration of RLP-TG reference range in the Japanese population
[96].
The simultaneous measurement of TG and cholesterol in RLP
resulted in a RLP-TG/RLP-C ratio which reﬂects the RLP particle size, as
shown by the HPLC proﬁle reported by Okazaki et al. [97]. The RLP-TG/
RLP-C ratios showed a variety of the RLP particle sizes in various lipid
disorders and under different physiological conditions; for example,
Type III cases exhibited a signiﬁcantly lower RLP-TG/RLP-C ratio
which indicated the presence of a higher cholesterol content in RLP
(mainly IDL), while the RLP-TG/RLP-C ratio was increased signiﬁ-
cantly in the postprandial state, indicating a signiﬁcantly increased TG
content in RLP (mainly large VLDL), as shown in Fig. 5. Therefore, theRLP-TG/RLP-C ratio predicted the particle size of RLP in a manner
comparable with the HPLC proﬁle.
Although RLP-C also increased after an oral fat load, the changes in
the RLP-C/total TG ratio in the postprandial state were not signiﬁcantly
different from the ratio in the fasting state. This is because the
percentage of RLP-C in the total TG (RLP-C/total TG ratio) was
approximately only 5% in the fasting and 4% in the postprandial state.
However, a RLP-C/total TG ratio above 10% in the fasting state is now
commonly used for the detection of Type III hyperlipidemia [62,63,98].
In contrast, the RLP-TG/total TG ratio was approximately 10–15% in the
fasting state, and the ratio increased signiﬁcantly to more than 40% in
the postprandial state. Therefore, we investigated the postprandial
changes in the RLP-TG/total TG ratio after an oral fat load [48,96]. The
postprandial RLP-TG/total TG ratio increasedmore than 3 fold in 2 h and
RLP-TG made up almost half of the total TG (Table 2). In terms of total
TG, we have also studied the TRL-TG ratio with RLP-TG, which is the
major fraction of the total TG as VLDL (db1.006). The RLP-TG/TRL-TG
ratio changed signiﬁcantly more than the RLP-TG/total TG ratio.
The particle size predicted by the RLP-TG/RLP-C ratio reﬂects a
signiﬁcant time-dependent increase of TG in RLP particles in the
postprandial state. RLP-TG increased 5.3 fold in 4 h, while RLP-C
increased 1.5 fold, as shown in Table 2. Therefore, we have found that
RLP-TG is a better maker than RLP-C for a direct comparison with total
TG in the postprandial state. The RLP-TG/total TG ratio may reﬂect LPL
activity, because LPL activity was shown to be inversely correlated with
the concentration of RLP and TG [33]. If a subject has a fasting RLP-TG/
total TG ratio above 0.13 (95%percentile in TG less than150 mg/dL) [96]
or anRLP-TGabove20 mg/dL in the fasting state, itmaybea subjectwho
is still in the postprandial state and this reﬂects the delayed remnant
lipoprotein metabolism because of disturbed LPL activities. A higher
RLP-TG/total TG ratio may be associated with an increased risk for CHD
[29,58,59,99].
10. Characteristics of the RLP isolated from postprandial plasma
As reportedbyKarpeet al. [29], CM ismore susceptible to lipoprotein
lipase (LPL) than is VLDL. Therefore, the greater susceptibility to LPL of
CM rather than VLDL may more readily result in the formation and
accumulation of VLDL remnants than CM remnants in the postprandial
state. Therefore, the accumulation of large RLP particles in 4 h after an
oral fat load may be due to the delayed metabolism of VLDL by LPL.
1315K. Nakajima et al. / Clinica Chimica Acta 412 (2011) 1306–1318Schneeman et al. [100] also reported the postprandial responses (after
fat load) of apoB-48 and apoB-100 were highly correlated with those of
TRL triglycerides. Although the increase in apoB-48 represented a 3.5-
fold difference in concentration as compared with a 1.6-fold increase in
apoB-100, apoB-100 accounted for approximately 80% of the increase in
lipoprotein particles in TRL. The increase in the number of apoB-100
particles in RLP (VLDL remnants) is actually far greater than that of the
apoB-48 particles (CM remnants) in the postprandial state [100,101].
TheRLP isolated fromplasma in healthy subjects after anoral fat load
using an immunoafﬁnity mixed gel was signiﬁcantly increased [48].
Fig. 5 shows the typical proﬁle of RLP particle size in the range of VLDL to
LDL at 0, 2, 4 and 6 h after an oral fat load,whenmonitored by TC and TG
with HPLC in a normolipidemic and hyperlipidemic subject, respective-
ly. CM or CM remnants (apoB48) could be detected at void volume (a
retention timeof 15 min). Fig. 7 shows a typical RLPproﬁle isolated from
the plasma of a Type IIb hyperlipidemic subject 4 h after an oral fat load.
RLP was fractionated by HPLC equipped with gel permeation columns
(TSK Lipopropak XL, Toso, Tokyo) [76] and 0.35 mL of aliquot each was
collected for thedetermination of TC, TG, apoB-48andapoB-100 (Fig. 7).
The peak of the TC and TG retention time in RLP fractionated by HPLC
was observed almost at the same particle size as the apoB-100 peak, but
was not the same as the apoB48 peak, as shown in Fig. 7. Furthermore,
the apoB-48 particle size was similar or smaller than that of apoB-100.
These results clearly demonstrate that postprandial RLP do not have
any apoB-48 particles carrying a large amount of TG in the void fraction,
which may thus be categorized as nascent CM [75,76]. The scale
(perpendicular axis) of the apoB-100 (left) and apoB-48 (right)
concentration in Fig. 7 is 4 fold different, but there are similar areas
under the curve. Therefore, the signiﬁcantly higher concentrations of
apoB-100 than apoB-48 in postprandial RLP of similar particle sizewere
found in both normolipidemic and hyperlipidemic cases [48]. These
results show that approximately 80% of the RLP in the postprandialFig. 7. A typical proﬁle of postprandial RLP in a hyperlipidemic subject. RLP was isolated and
level: TC; 238, TG; 196, HDL-C; 53, LDL-C; 111, RLP-C; 7.0, RLP-TG; 69, apoB; 92, apoB48; 0.8
total cholesterol (TC) and triglycerides (TG) (top) as well as for apoB-48 and apoB-100 (bott
than that of apoB-48 (right), but displays a similar area under the curve. Themajor particles in
CM as monitored by apoB-48.
Ref. [48]: Nakano et al., Ann Clin Biochem. 2011; 48: 57–64.state is composed of large VLDL with apoB100. The increase of small
VLDL such as intermediate density lipoproteins (IDL, Sf 12–20) in the
postprandial state has been reported to not be increased in the
postprandial state [12,102], even though IDL has often been deﬁned as
a typical remnant lipoprotein.
11. Postprandial remnant hyperlipoproteinemia in sudden cardiac
death (SCD)
Clinical studies have shown that elevated plasma TG levels greatly
increase the risk of sudden cardiac death. Results from the Paris
Prospective Study [103] and the Apolipoprotein Related Mortality Risk
Study (AMORIS) in Sweden [104] as well as the coronary heart disease
mortality in a 24-year follow-up study inChina [105] demonstrated that
increased TG was a strong risk factor for fatal myocardial infarction.
However, plasma TG levels vary often over even a short period of time.
Therefore, it has been difﬁcult to identify the relationship between
clinical events and elevatedTG in the long termprospective studies until
recently [3–5].
If the lipid and lipoprotein levels in postmortem plasma correctly
reﬂect the antemortem levels, these data would provide the same
values with the results obtained from the prospective studies, which
are difﬁcult to obtain in that they require long-term observation to
evaluate. The plasma levels of lipids and lipoproteins in sudden death
cases may reﬂect the condition of the subject at the moment of fatal
clinical events followed by certain inevitable postmortem alterations,
but nevertheless still usefully reﬂect the physiological conditions
when the fatal events had occurred. Therefore, we analyzed
postmortem plasma under well-controlled conditions to clarify the
cause or risk of sudden cardiac death. Plasma RLP-C and RLP-TG levels
vary greatly within a short time do the TG levels, unlike other stable
lipoprotein markers such as HDL-C and LDL-C. Hence, the cross-fractionated by HPLC from the postprandial plasma of a hyperlipidemic subject (fasting
6 mg/dL) (in) 4 h after an oral fat load. The RLP fractionated by HPLC was monitored for
om). The scale (perpendicular axis) of the apoB-100 (left) concentration is 4 fold higher
RLPwere of VLDL size asmonitored by apoB-100, and the comparatively smaller size of
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superior to a prospective study of RLP in determining the potential
risk for CHD [106]. During the investigations of sudden death cases,
we found that the postmortem alterations of lipoproteins in plasma
were unexpectedly slight [107] compared with the proteins or other
bio-markers. Moreover, these plasma lipoprotein levels were very
similar to those determined in living patients, based on the clinical
studies in our laboratory.
More than two thirds of the SCD cases observed in our studies,
including Pokkuri death syndrome (PDS; sudden cardiac death cases
without coronary atherosclerosis), showed stomach full, indicating a
strong association with postprandial remnant hyperlipoproteinemia.
Signiﬁcant remnant hyperlipoproteinemia was observed in the
plasma of SCD cases compared with the control death cases
[68,101,108–112]. These data suggest that the increased RLP in SCD
cases may be mainly composed of CM remnants. However, unexpect-
edly, we found no signiﬁcant differences in the apoB-48 levels in
plasma or in terms of RLP apoB48, but found a signiﬁcant increase of
RLP apoB100 levels in SCD compared to the control cases [101]. The
RLP apoB100 levels were signiﬁcantly increased in the SCD cases in
the postprandial state (when RLP-C and RLP-TG were signiﬁcantly
increased), however, neither the plasma apoB48 nor RLP apoB48 level
was signiﬁcantly increased. These results strongly suggested that the
major subset of RLP associated with fatal clinical events with the
stomach full was the apoB-100 carrying particles, not the apoB-48
particles.
The absolute amount of apoB-100 in RLP is much greater
(approximately 7 fold) than that of apoB-48 in RLP. Also the particle
size of apoB-48 and apoB-100 was very similar, as shown in Fig. 7
[112]. Furthermore, we often found SCD cases who had consumed
alcohol on a full stomach. It is known that alcohol increases fatty acids
in the liver and enhances VLDL production while inhibiting LPL
activity [113]. Alcohol intake with a fatty meal is well known to
greatly increase TG in the postprandial state. The intake of alcohol
together with a fatty meal may thus enhance the production of
apoB100 carrying VLDL in the liver and increase VLDL remnants by
inhibiting LPL activity, resulting in an increase in the potential risk of
coronary artery in SCD cases [114].
12. Conclusions
Three new analytical methods were used to investigate the
characteristics of postprandial lipoprotein metabolism. These were a
method of isolating the remnant lipoproteins as RLP using speciﬁc
antibodies, gel permeationHPLCandapoB48ELISA. Themajor portion of
the TG which increased in the postprandial state was shown to be TRL
remnant lipoproteins. Although Zilversmit proposed CM or CM
remnants as themajor lipoproteinswhich increased in the postprandial
lipemia, we have shown that the major portion of the postprandial
lipoproteins which increased after food intake was composed of VLDL
remnants. The amount of apoB48particleswas shown to bemuch lower
than apoB100 particles in the postprandial RLP, and the particle sizes of
apoB48 in RLP were similar with those of apoB100 or smaller when
analyzed by gel permeation HPLC system. We did not ﬁnd CM or CM
remnants having a large amount of TG in postprandial RLP. Therefore,
the major part of postprandial TRL remnants is composed of VLDL
remnants (approximately 80% or more), not CM remnants. It was also
found that TG vs RLP-TG concentrations in the postprandial state
correlated signiﬁcantly higher than in the fasting state. Furthermore,
it was demonstrated that approximately 80% of the increased TG in
the postprandial state consisted of the TG in remnant lipoproteins.
Taken together, we propose the following equation for the estimated
concentration of the increased remnant lipoproteins in the postprandial
plasma; (Postprandial TG−Fasting TG)×0.8=RLP-TG, to reﬂect the
increase in the postprandial plasma as being mainly composed of VLDL
remnants.Acknowledgments
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